glp-1 obesity drug news today oct 2025 Poll: 1 in 8 Adults Say They Are Currently Taking a for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford Amgen Reshapes the Obesity Drug

doi: 10.3233/JAD-2010-1314 [DOI] [PMC free article] [PubMed] [Google Scholar] 152

Real-world data cited in the paper suggest roughly half of patients discontinue treatment within a year of starting it a rate far higher than the trials, with their closer supervision, capture

Coverage gaps, steep out-of-pocket costs, and payer-imposed roadblocks stall progress before treatment even begins, while stigma, fragmented care, and shifting patient perceptions chip away at long-term adherence

The absorption enhancer salcaprozate sodium poses theoretical risks to the nursing infant

This year's Lasker~DeBakey Clinical Medical Research Award recognizes Joel Habener, Svetlana Mojsov, and Lotte Knudsen for their essential roles in making this possible

In overweight or obese patients with NAFLD, reduction in body weight 710% improves liver enzymes together with the histological grade of disease [66,67]